Superoxide anion release from neutrophils in growth hormone deficient adults before and after replacement therapy with recombinant human growth hormone.

What Was Tested

The paper reports a study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over), published as a randomized controlled trial.

Whether leukocyte function is impaired in growth hormone deficient adults is not known as yet.

Analyses were performed by comparing functions of the leukocytes from these patients with those from age and sex-matched healthy control subjects.

Who Took Part

According to the abstract, 15 patients were involved.

PubMed indexes the participants as adults and middle-aged adults, both men and women.

How the Study Was Run

In design terms this was a randomized and double-blind study.

The patients were allocated by chance, so the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) group and the comparison group should start out alike.

Neither the patients nor the staff measuring them knew who was on Exogenous HGH, sermorelin & older GHRPs (why they're passed over), so expectations could not easily colour the readings.

What Was Measured

PubMed files the paper under topics including Chemotaxis, Leukocyte, Human Growth Hormone, Insulin-Like Growth Factor I, Neutrophils, Recombinant Proteins, Respiratory Burst and Superoxides.

What This Means in Plain Language

The paper is a randomized and double-blind study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over) in 15 patients.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

The publication is from 1997 (Naunyn-Schmiedeberg's archives of pharmacology), a journal based in Germany.

More context: the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) compound page, all human trials.